



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Jean-Louis TOURAINE et al.

Group Art Unit: 1645

Application No.: 10 024,329

Examiner:

Filed: December 21, 2001

Docket No.: 109993

For: GENE THERAPY USING ANTI-GP41 ANTIBODY AND CD4 IMMUNOADHESIN

INFORMATION DISCLOSURE STATEMENT

Director of the U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

William P. Berridge  
Registration No. 30,024

Melanie L. Mealy  
Registration No. 40,085

WPB:MLM/jam


Date: June 4, 2002

OLIFF & BERRIDGE, PLC  
P.O. Box 19928  
Alexandria, Virginia 22320  
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE  
AUTHORIZATION  
Please grant any extension  
necessary for entry;  
Charge any fee due to our  
Deposit Account No. 15-0461

RECEIVED

RECEIVED 1600/2900




RECEIVED

Sheet 1 of 4

Form PTO-1449 (REV. 8-83)		U.S. Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 109993		APPLICATION NO. 10 024 329	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANT(S) Jean-Louis TOURAINE et al.			
				FILING DATE December 21, 2001		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUB CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
		D.D. HO et al., "Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection." <u>Nature</u> , Vol. 373, pp. 123-126, January 1995.					
		D.D. HO et al., "Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected Persons." <u>The New England Journal of Medicine</u> , Vol. 321, No. 24, pp. 1621-1625, December 1989.					
		G. PANTALEO et al., "HIV Infection is Active and Progressive in Lymphoid Tissue During the Clinically Latent Stage of Disease." <u>Nature</u> , Vol. 362, pp. 355-358, March 1993.					
		M. PIATAK, Jr., et al., "High Levels of HIV-1 in Plasma During All Stages of Infection Determined by Competitive PCR." <u>Science</u> , Vol. 259, pp. 1749-1754, March 1993.					
		J.M. McCUNE et al., "The SCID-hu Mouse Murine Model for the Analysis of Human Hematolymphoid Differentiation and Function." <u>Science</u> , Vol. 241, pp. 1632-1639, September 1988.					
		K. SANHADJI et al., "Long-Term Chimera Produced by Transplantation of Human Fetal Liver Cells Into Severe Combined Immunodeficiency Mice." <u>Transplantation Proceedings</u> , Vol. 25, No. 1, pp. 452, February 1993.					
		R. NAMIKAWA et al., "Infection of the SCID-hu Mouse by HIV-1." <u>Science</u> , Vol. 242, pp. 1684-1686, December 1988.					
		E.A. EMINI et al., "Prevention of HIV-1 Infection in Chimpanzees by gp120 V3 Domain-Specific Monoclonal Antibody." <u>Nature</u> , Vol. 355, pp. 728-730, February 1992.					
		G. PANTALEO et al., "Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection." <u>New England Journal of Medicine</u> , Vol. 332, No. 4, pp. 209-216, January 1995.					
		A. LI et al., "Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins." <u>AIDS Research and Human Retrovirus</u> , Vol. 13, No. 8, pp. 647-656, 1997.					
		T. SCHACKER et al., "Phase I Study of High-Dose, Intravenous rsCD4 in Subjects with Advanced HIV-1 Infection." <u>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</u> , Vol. 9, No. 2, pp. 145-152, 1995.					
		T.C. MENG et al., "Combination Therapy with Recombinant Human Soluble CD4-Immunoglobulin G and Zidovudine in Patients with HIV Infection: A Phase I Study." <u>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</u> , Vol. 8, No. 2, pp. 152-160, 1995.					
		R.A. MORGAN et al., "Further Evaluation of Soluble CD4 as an Anti-HIV Type 1 Gene Therapy: Demonstration of Protection of Primary Human Peripheral Blood Lymphocytes from Infection by HIV Type 1." <u>AIDS Research and Human Retroviruses</u> , Vol. 10, No. 11, pp. 1507-1515, 1994.					
		T. MUSTER et al., "A Conserved Neutralizing Epitope on gp41 of Human Immunodeficiency Virus Type 1." <u>Journal of Virology</u> , Vol. 67, No. 11, pp. 6642-6647, November 1993.					
EXAMINER						DATE CONSIDERED	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: June 4, 2002




RECEIVED

TECH CENTER 180-2900

Sheet 2 of 4


Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 109993		APPLICATION NO. 10 024,329	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANT(S) Jean-Louis TOURAINE et al.			
				FILING DATE December 21, 2001		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
		P.L. NARA et al., "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection Human Immunodeficiency Virus Neutralizing Antibody," <u>AIDS Research and Human Retroviruses</u> , Vol. 3, No. 3, pp. 283-302, 1987.					
		A. BUCHACHER et al., "Generation of Human Monoclonal Antibodies Against HIV-1 Proteins: Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization," <u>AIDS Research and Human Retroviruses</u> , Vol. 10, No. 4, pp. 359-369, 1994					
		T. MUSTER et al., "Cross-Neutralizing Activity Against Divergent Human Immunodeficiency Virus Type 1 Isolates Induced by the gp41 Sequence ELDKWAS," <u>Journal of Virology</u> , Vol. 68, No. 6, pp. 4031-4034, June 1994.					
		P. W.H.I. PARREN et al., "Protection Against HIV-1 Infection in hu-PBL-SCID Mice by Passive Immunization with a Neutralizing Human Monoclonal Antibody Against the gp120 CD4-binding Site," <u>AIDS</u> , Vol. 9, No. 6, pp. F1-F6, 1995.					
		L. ANDRUS, et al., "Passive Immunization with a Human Immunodeficiency Virus Type 1-Neutralizing Monoclonal Antibody in Hu-PDL-SCID Mice: Isolation of a Neutralization Escape Variant," <u>Journal of Infectious Disease</u> , Vol. 177, pp. 889-897, April 1998.					
		D.H. SMITH et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen," <u>Science</u> , Vol. 238 pp. 1704-1707, December 1987.					
		K. C. DEEN et al., "A Soluble Form of CD4 (T4) Protein Inhibits AIDS Virus Infection," <u>Nature</u> , Vol. 331, pp. 82-84 January 1988.					
		R.A. BYRN et al., "Characterization of In Vitro Inhibition of Human Immunodeficiency Virus by Purified Recombinant CD4," <u>Journal of Virology</u> , Vol. 63, No. 10, pp. 4370-4375, October 1989.					
		D.J. CAPON et al., "Designing CD4 Immunoadhesins for AIDS Therapy," <u>Nature</u> , Vol. 337, pp. 525-531, February 1989.					
		G.P. ALLAWAY et al., "Expression and Characterization of CD4-IgG <sub>2</sub> , A Novel Heterotetramer that Neutralizes Primary HIV Type 1 Isolates," <u>AIDS Research and Human Retroviruses</u> , Vol. 11, No. 5, pp. 533-539, 1995.					
		H. TSUBOTA et al., "CD4-Pseudomonas Exotoxin Conjugates Delay but Do Not Fully Inhibit Human Immunodeficiency Virus Replication in Lymphocytes in Vitro," <u>J. Clin. Invest.</u> , Vol. 86, pp. 1684-1689, November 1990.					
		S. DEMARIA et al., "Soluble CD4 Induces the Binding of Human Immunodeficiency Virus Type 1 to Cells via the V3 Loop of Glycoprotein 120 and Specific Sites in Glycoprotein 41," <u>AIDS Research and Human Retroviruses</u> , Vol. 12, No. 4, pp. 281-290, 1996.					
		Q.J. SATTENTAU et al., "Epitope Exposure on Functional, Oligomeric HIV-1 gp41 Molecules," <u>Virology</u> , Vol. 206, pp. 713-717, 1995.					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: June 4, 2002

RECEIVED  
TECH. CENTER - 100 2000 Sheet 3 of 4

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 109993		APPLICATION NO. 10 024.329	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANT(S) Jean-Louis TOURAINE et al.			
				FILING DATE December 21, 2001		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
		E. SHINYA et al., "In-Vivo Delivery of Therapeutic Proteins by Genetically-Modified Cells: Comparison of Organoids and Human Serum Albumin Alginate-Coated Beads." <i>Biomed &amp; Pharmacother.</i> Vol. 53, pp. 471-483, 1999.					
		F. BARRE-SINOUSSE et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)." <i>Science</i> , Vol. 220, pp. 868-870, May 1983.					
		R.C. GALLO et al., "Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS." <i>Science</i> , Vol. 224, pp. 500-503, May 1984.					
		S. WAIN-HOBSON et al., "Nucleotide Sequence of the AIDS Virus, LAV," <i>Cell</i> , Vol. 40, pp. 9-17, January 1985.					
		L. RATNER et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III," <i>Nature</i> , Vol. 313, pp. 277-284, January 1985.					
		H. KATINGER et al., "Results of Preclinical Screening and Epitope Mapping of Human Monoclonal Antibodies Against HIV-1." <i>Septieme Colloque Des Cant Gardes</i> , Vienna, Austria, pp. 299-303, 1992					
		P.D. ROBBINS et al., "Viral Vectors for Gene Therapy." <i>TibTech</i> , Vol. 16, pp. 35-40, January 1998.					
		P.L. FELGNER et al., "Cationic Liposome Mediated Transfection," <i>Proc. West. Pharmacol. Soc.</i> Vol. 32, pp. 115-121, 1989.					
		C.P. HODGSON et al., "Virosomes: Cationic Liposomes Enhance Retroviral Transduction." <i>Nature Biotechnology</i> , Vol. 14, pp. 339-342, March 1996.					
		J. REMY et al., "Gene Transfer with a Series of Lipophilic DNA-Binding Molecules." <i>Bioconjugate Chem.</i> , Vol. 5, No. 6 pp. 647-654, 1994.					
		R. LATHE et al., "Plasmid and Bacteriophage Vectors for Excision of Intact Inserts." <i>Gene</i> , Vol. 57, pp. 193-201, 1987.					
		S. LUPTON et al., "Mapping Genetic Elements of Epstein-Barr Virus that Facilitate Extrachromosomal Persistence of Epstein-Barr Virus-Derived Plasmids in Human Cells." <i>Molecular and Cellular Biology</i> , Vol. 5, No. 10, pp. 2533-2542, October 1985.					
		J.L. YATES et al., "Stable Replication of Plasmids Derived from Epstein-Barr Virus in Various Mammalian Cells." <i>Nature</i> , Vol. 313, pp. 812-815, February 1985.					
		D.K. SUMMERS et al., "Multimerization of High Copy Number Plasmids Causes Instability: ColE1 Encodes a Determinant Essential for Plasmid Monomerization and Stability," <i>Cell</i> , Vol. 36, pp. 1097-1103, April 1984.					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: June 4, 2002



Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 109993		APPLICATION NO. 10 024.329	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANT(S) Jean-Louis TOURAINE et al.			
				FILING DATE December 21, 2001		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
		N. CHINNASAMY et al., "Efficient Gene Transfer to Human Peripheral Blood Monocyte-Derived Dendritic Cells Using Human Immunodeficiency Virus Type 1-Based Lentiviral Vectors." <u>Human Gene Therapy</u> , Vol. 11, pp. 1901-1909, September 2000.					
		M.D. BROWN et al., "Gene Delivery with Synthetic (non viral) Carriers." <u>International Journal of Pharmaceutics</u> , Vol. 229 pp. 1-21, 2001.					
		F.L. GRAHAM et al., "Manipulation of Adenovirus Vectors." <u>Methods of Molecular Biology</u> , Vol. 7, pp. 109-128, 1991.					
		A.N. ZAKHARCHUK et al., "Physical Mapping and Homology Studies of Egg Drop Syndrome (EDS-76) Adenovirus DNA." <u>Archives of Virology</u> , Vol. 128, pp. 171-176, 1993.					
		N. SPIBEY et al., "Molecular Cloning and Restriction Endonuclease Mapping of Two Strains of Canine Adenovirus Type 2." <u>J. Gen. Virol.</u> , Vol. 70, pp. 165-172, 1989.					
		P. JOUVENNE et al., "Cloning, Physical Mapping and Cross-Hybridization of the Canine Adenovirus Types 1 and 2 Genomes." <u>Gene</u> , Vol. 60, pp. 21-28, 1987.					
		S.K. MITTAL et al., "Development of a Bovine Adenovirus Type 3-based Expression Vector." <u>Journal of General Virology</u> , Vol. 76, pp. 93-102, 1995.					
		C.J. TABIN et al., "Adaptation of a Retrovirus as a Eucaryotic Vector Transmitting the Herpes Simplex Virus Thymidine Kinase Gene." <u>Molecular and Cellular Biology</u> , Vol. 2, No. 4, pp. 426-436, April 1982.					
		Y. TAKEBE et al., "SR $\alpha$ Promotor: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat." <u>Molecular and Cellular Biology</u> , Vol. 8, No. 1, pp. 466-472, January 1988.					
		L. CHEN et al., "Breast Cancer Selective Gene Expression and Therapy Mediated by Recombinant Adenoviruses Containing the DF3/MUC1 Promoter." <u>J. Clin. Invest.</u> , Vol. 96, pp. 2775-2782, December 1995.					
		H. SCHREWE et al., "Cloning of the Complete Gene for Carcinoembryonic Antigen: Analysis of its Promoter Indicates a Region Conveying Cell Type-Specific Expression." <u>Molecular and Cellular Biology</u> , Vol. 10, No. 6, pp. 2738-2748, June 1990.					
		R.G. VILE et al., "Use of Tissue-specific Expression of the Herpes Simplex Virus Thymidine Kinase Gene to Inhibit Growth of Established Murine Melanomas Following Direct Intratumoral Injection of DNA." <u>Cancer Research</u> , Vol. 53, pp. 3860-3864, September 1993.					
		J.D. HARRIS et al., "Gene Therapy for Cancer using Tumor-specific Prodrug Activation." <u>Gene Therapy</u> , Vol. 1, pp. 170-175, 1994.					
		F. KANAI et al., "In Vivo Gene Therapy for $\alpha$ -Fetoprotein-producing Hepatocellular Carcinoma by Adenovirus-mediated Transfer of Cytosine Deaminase Gene." <u>Cancer Research</u> , Vol. 57, pp. 461-465, February 1997.					
		R.S. McIVOR et al., "Human Purine Nucleoside Phosphorylase and Adenosine Deaminase: Gene Transfer into Cultured Cells and Murine Hematopoietic Stem Cells by Using Recombinant Amphotropic Retroviruses." <u>Molecular and Cellular Biology</u> , Vol. 7, No. 2, pp. 838-846, February 1987.					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: June 4, 2002